Stock 4553 TOWA PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Towa Pharmaceutical Co., Ltd.

Equities

4553

JP3623150004

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-05-31 am EDT 		5-day change 1st Jan Change
2,890 JPY +2.37% Intraday chart for Towa Pharmaceutical Co., Ltd. +2.70% +22.87%
May. 22 Towa Pharmaceutical Co., Ltd. Announces Board and Committee Resignations CI
Mar. 25 Towa Pharmaceutical Completes Payment for Director Stock Compensation MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • One of the major weak points of the company is its financial situation.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
TOWA PHARMACEUTICAL CO., LTD. Stock Towa Pharmaceutical Co., Ltd.
+22.87% 887M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 734B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 591B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 350B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 315B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.05% 276B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 238B
B+
NOVARTIS AG Stock Novartis AG
+9.78% 206B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 204B
A+
AMGEN INC. Stock Amgen Inc.
+6.17% 161B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4553 Stock
  4. Ratings Towa Pharmaceutical Co., Ltd.